We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tel Aviv, Israel, March 06, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of an...
Diversifies Seelos’ pipeline in rare diseases Collaborates with Team Sanfilippo Foundation in development of Trehalose in Sanfilippo syndrome NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Seelos...
Unconditional payment of $3.5 million Contingent payment of up to additional $17 million plus royaltiesSeelos to receive rights also to the Trehalose for Sanfilippo Syndrome Program Tel Aviv...
Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo...
Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company...
Enlivex Therapeutics is a private, venture-funded clinical stage immunotherapy company developing an allogeneic drug pipeline for immune system rebalancing, which is critical for the treatment of...
TEL AVIV, Israel and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN) is providing an update on business development activities as well as notice of an...
TEL AVIV, Israel, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for...
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on September 25, 2017 TEL AVIV, Israel, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM:ORPN), a...
Patients Treated with Trehalose Remained Stable According to a Well-Established Clinical Evaluation Scale A Recent Natural History Study in The Lancet Neurology in Patients with SCA3 Noted a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions